Stock Information
Arrowhead Pharmaceuticals Inc (ARWR)
Ticker Symbol: ARWR
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $10,351.18 mil
Piotroski score: 5
PE Ratio: 51.7925
EPS (TTM): 1.5409
Revenue (TTM): $7.75 M
Dividend Yield: N/A%
ROE: 36.12%
Latest News
-
This Littelfuse Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Fri, May 1, 2026 2:50 PM
-
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Fri, May 1, 2026 11:30 AM
-
JP Morgan Initiates Coverage On Arrowhead Pharma with Overweight Rating, Announces Price Target of $88
Fri, May 1, 2026 8:29 AM
-
Arrowhead Pharma Says Australian TGA Approves REDEMPLO, siRNA Medicine, As Adjunct To Diet To Reduce Triglyceride Levels For Adult Patients With Familial Chylomicronemia Syndrome
Fri, May 1, 2026 7:33 AM
-
What's going on in today's after hours session
Wed, Apr 29, 2026 9:00 PM
-
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
Wed, Apr 29, 2026 5:00 PM
-
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe
Mon, Apr 27, 2026 7:05 AM
Key Financials
Financial data not available
